LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $9.00

LifeStance Health Group (NASDAQ:LFST) had its target price hoisted by KeyCorp from $8.00 to $9.00 in a report issued on Thursday morning,Benzinga reports. KeyCorp currently has an overweight rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Barclays initiated coverage on shares of LifeStance Health Group in a research note on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price objective for the company. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday, December 29th. UBS Group upped their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Finally, BMO Capital Markets initiated coverage on LifeStance Health Group in a research note on Thursday, November 13th. They set an “outperform” rating and a $8.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, LifeStance Health Group has an average rating of “Moderate Buy” and a consensus target price of $9.67.

LifeStance Health Group Stock Performance

NASDAQ:LFST opened at $7.24 on Thursday. The business’s fifty day moving average is $7.13 and its 200 day moving average is $6.21. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of 362.18 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Wednesday, February 25th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.02). The company had revenue of $382.20 million during the quarter, compared to the consensus estimate of $378.51 million. LifeStance Health Group had a return on equity of 0.66% and a net margin of 0.68%.The firm’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.01) EPS. Research analysts predict that LifeStance Health Group will post -0.18 EPS for the current year.

LifeStance Health Group declared that its Board of Directors has initiated a stock repurchase program on Wednesday, February 25th that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the company to purchase up to 3.6% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In other news, Director Robert Bessler sold 119,942 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $7.04, for a total value of $844,391.68. Following the completion of the transaction, the director directly owned 1,318,983 shares in the company, valued at approximately $9,285,640.32. This represents a 8.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ann Varanakis sold 50,000 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total value of $345,000.00. Following the transaction, the insider owned 315,610 shares in the company, valued at $2,177,709. This trade represents a 13.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 270,086 shares of company stock worth $1,891,264. 3.20% of the stock is owned by insiders.

Institutional Trading of LifeStance Health Group

A number of hedge funds have recently bought and sold shares of LFST. Larson Financial Group LLC boosted its stake in LifeStance Health Group by 19,952.6% in the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after buying an additional 3,791 shares in the last quarter. Bayesian Capital Management LP bought a new stake in shares of LifeStance Health Group in the 2nd quarter worth approximately $52,000. Krane Funds Advisors LLC purchased a new stake in shares of LifeStance Health Group in the 4th quarter valued at $71,000. Cibc World Markets Corp bought a new position in shares of LifeStance Health Group during the 4th quarter valued at $77,000. Finally, Qtron Investments LLC bought a new position in shares of LifeStance Health Group during the 4th quarter valued at $83,000. Institutional investors own 85.50% of the company’s stock.

Key LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Board authorizes a $100 million share repurchase (up to ~3.6% of shares), signaling management thinks the stock is undervalued and reducing float. LifeStance to Repurchase $100M
• Positive Sentiment: Multiple firms raised price targets and ratings (UBS to $12, Canaccord to $10, KeyCorp to $9), increasing visible upside and buy-side interest. Analyst Price Target Raises
• Positive Sentiment: Company set 2026 revenue target of $1.615B–$1.655B and highlighted progress on AI and EHR initiatives that can drive scale and margin expansion over time. 2026 Revenue Target & Initiatives
• Neutral Sentiment: Coverage roundup: several analysts reviewed the stock following the quarter; the market reaction depends on whether upgrades translate into sustained buy-side flows. 6 Analysts Assess LFST
• Negative Sentiment: Q4 EPS missed expectations (reported ~$0.03 vs. ~$0.06 expected) despite revenue beating estimates; EPS weakness and still-modest margins remain near-term headwinds. Q4 2025 Earnings Highlights
• Negative Sentiment: Selling stockholders filed a secondary offering of 25M shares (company not raising proceeds), creating potential supply/overhang that can cap near-term upside. Secondary Public Offering

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.